STRABEN rollers are indicated for short-term symptomatic relief of sore throat in adults and children over 12 years of age…
STRABEN rollers are indicated for short-term symptomatic relief of sore throat in adults and children over 12 years of age. Each roller contains 8.75 mg of flurbiprofen. Adjuvants with known action: Lactose, sorbitol.
Adults and children over 12 years:
A roll is slowly loosened / dissolved in the mouth every 3-6 hours, if necessary.
Maximum dosage: 5 rounds over a 24-hour period.
It is recommended that the product be given for up to 3 days.
Not suitable for children under 12 years of age.
A general dosage cannot be proposed as the clinical experience to date of medicinal products of flurbiprofen is limited.
Elderly people are at increased risk of suffering the serious consequences of side effects.
Patients with renal impairment:
In patients with mild to moderate renal impairment, no dose reduction is required.
In patients with severe renal impairment, flurbiprofen is contraindicated
Patients with hepatic impairment:
Patients with mild to moderate hepatic insufficiency do not require dose reduction.
In patients with severe hepatic impairment, flurbiprofen is contraindicated
Packaging: 20 rolls
Undesirable effects can be minimized using the lowest effective dose and the shorter duration of treatment required to control the symptoms.
Elderly people are at greater risk of having unwanted effects with NSAIDs, particularly gastric bleeding or perforation that may be fatal.
Bronchospasm can be triggered in patients suffering from bronchial asthma or allergic disease or a history of these conditions. STRABEN should be carefully administered to these patients.
Coadministration of STRABEN with other NSAIDs including COX-2 inhibitors should be avoided.
Systemic lupus erythematosus and mixed connective tissue disease
Systemic lupus erythematosus and mixed connective tissue disease increase the risk of aseptic meningitis, although this unwanted effect is not usually seen in short-term and limited use of products such as flurbiprofen.
Heart, kidney and liver dysfunction
It has been reported that NSAIDs cause nephrotoxicity in various forms such as interstitial nephritis, nephrotic syndrome and renal failure. NSAID administration may cause a dose-dependent decrease in prostaglandin synthesis and renal failure. Patients at greatest risk are those with impaired renal function, heart failure, hepatic dysfunction, diuretics and the elderly. However, nephrotoxicity is not usually observed in short-term limited use of products, such as the flurbiprofen
Renal impairment from analgesics
Exclusive use of analgesics can lead to permanent kidney damage with a risk of renal insufficiency, especially with a combination of different analgesics, but this is not usually seen in short-term and limited use of products such as STRABEN castors.
Cardiovascular and cerebrovascular effects
Appropriate monitoring and advice is required in patients with a history of hypertension and / or heart failure, as fluid retention, hypertension and edema have been reported in combination with NSAID therapy.
Data from clinical trials and epidemiological data suggest that the use of NSAIDs (particularly at high doses and for long-term treatment) may be associated with a slightly increased risk of developing arterial thrombotic events (for example, myocardial infarction or stroke). There is insufficient data to rule out such a risk for flurbiprofen when given in a daily dose of up to 5 rounds.
In patients with uncontrolled hypertension, congestive heart failure, established cardiac ischemia, peripheral arterial disease, and / or cerebrovascular disease, flurbiprofen should be administered only after careful consideration
Effects on the Nervous System
Headache caused by analgesics. In case of prolonged use of analgesics or inappropriate use, headache may occur which should not be treated with higher doses of the drug.
NSAIDs should be used with caution in patients with a history of gastrointestinal disorders as these conditions may worsen.
Gastrointestinal hemorrhage, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, with or without
warning symptoms or previous history of serious gastrointestinal events
The risk of gastrointestinal hemorrhage, ulceration or perforation is higher at higher doses of NSAIDs and in patients with a history of ulcers, particularly if they have had bleeding or puncture complications and in the elderly. However, these side effects are not usually observed in short-term use of products such as flurbiprofen pads.
Patients with a history of gastrointestinal toxicity, especially when they are elderly, are advised to report any unusual symptoms to their doctor.
Caution should be advised in patients receiving concomitant medications that may increase the risk of ulcer or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid.
If gastrointestinal hemorrhage or ulcer occurs in patients receiving flurbiprofen, treatment should be discontinued
Serious skin reactions, some of which may be fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in relation to the use of NSAIDs. The patient is advised to discontinue the preparation at the first appearance of skin rash, mucosal damage or any other hypersensitivity symptoms.
As in isolated cases the worsening of infectious inflammation has been reported in transient association with the administration of systemic NSAIDs, the patient is encouraged to consult a doctor immediately if signs of bacterial contamination appear during treatment with STRABEN. Consideration should be given to whether antimicrobial therapy is appropriate.
In cases of purulent bacterial pharyngitis / tonsillitis, STRABEN rollers should be administered in combination with antibiotic therapy.
Patients with rare hereditary problems of fructose and galactose intolerance, Lapp lactase deficiency or poor absorption of glucose-galactose should not take this medicine.
If the symptoms worsen or appear new, treatment should be re-evaluated.
If irritation of the mouth occurs, treatment should be discontinued.
-The indicated expiration date refers to packages that are intact and properly stored